PCX-12

KaliVir Immunotherapeutics has successfully completed the first cohort of its STEALTH-001 Phase 1/1b trial evaluating VET3-TGI in patients with advanced solid tumors.

GenVivo's lead candidate GEN2, a non-replicating mRNA vector therapy, demonstrates favorable safety profile with minimal toxicity and encouraging pharmacodynamic activity in Phase 1 trials for solid tumors.

Ankyra Therapeutics presented preliminary Phase 1 data for tolododekin alfa (ANK-101), an anchored IL-12 drug conjugate, showing well-tolerated dosing up to 250 µg/mL with no dose-limiting toxicities in 15 patients with metastatic solid tumors.

ImmVira presented Phase I clinical results for MVR-C5252, an oncolytic herpes simplex virus therapy targeting malignant glioma, at the 2025 AACR annual meeting.

Strand Therapeutics' STX-003 demonstrates first-in-class ability to target IL-12 expression specifically to tumor tissues when delivered systemically, potentially overcoming toxicity challenges that have limited cytokine therapies.